SkinBioTherapeutics (LSE:SBTX) ROCE % : -96.02% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is SkinBioTherapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. SkinBioTherapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -96.02%.

SkinBioTherapeutics ROCE % Historical Data

The historical data trend for SkinBioTherapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SkinBioTherapeutics ROCE % Chart

SkinBioTherapeutics Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

-37.51

-51.63

-38.40

-75.44

-129.27

SkinBioTherapeutics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial										-48.29	-106.68	-139.60	-196.25	-96.02

SkinBioTherapeutics ROCE % Calculation

SkinBioTherapeutics's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-2.999	/	( ( (3.085 - 0.509)	+	(2.594 - 0.53) )	/ 2 )
	=	-2.999	/	( (2.576	+	2.064)	/ 2 )
	=	-2.999	/	2.32
	=	-129.27 %

SkinBioTherapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-2.772	/	( ( (2.594 - 0.53)	+	(4.211 - 0.501) )	/ 2 )
	=	-2.772	/	( ( 2.064	+	3.71 )	/ 2 )
	=	-2.772	/	2.887
	=	-96.02 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

SkinBioTherapeutics (LSE:SBTX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

SkinBioTherapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of SkinBioTherapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

SkinBioTherapeutics (LSE:SBTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SkinBioTherapeutics PLC (LSE:SBTX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bath Lane, The Core, Newcastle Helix, Newcastle upon Tyne, GBR, NE4 5TF

Website

https://www.skinbiotherapeutics.com

SkinBioTherapeutics PLC is a life science company focused on skin health. It is focused on the development of technology to protect, manage, and restore skin utilizing proteins found in the human microbiota. It is targeting three specific skin healthcare sectors; cosmetics, infection control, and eczema.